Instead of a Cologuard version of the Sinatra standard, spots reference "Game of Thrones" and "Real Housewives." ...

Exact Sciences' 2024 sales grew 10% to $2.76 billion, exceeding estimates. New cancer tests, including Cologuard Plus, are ...

Leerink Partners analyst Puneet Souda has maintained their bullish stance on EXAS stock, giving a Buy rating yesterday.Stay Ahead of the ...

For example, a person might perform a Cologuard screening every three years, and if it turns positive—perhaps due to ...

2 “After having the same discussion year after year with my doctor, he mentioned that there are these Cologuard® box tests for colorectal cancer screening,” Leigh Anne said. “I was so ...

They’re non-invasive with none of the dreaded prep. But are recently approved home tests for colon cancer as effective as ...

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the ...

The last 12 months saw major regulatory changes for the field of gastroenterology, from new FDA approvals to sweeping statewide and national legislation. Here is what to know about a handful of recent ...

Unlike a colonoscopy, neither Shield nor Cologuard requires any special preparation, dietary modifications or sedation. “Shield reflects some of the current obstacles of screening,” Dr.

It developed Cologuard, a screening test for the early detection of colorectal cancer and pre-cancer. The company was founded on February 10, 1995 and is headquartered in Madison, WI.

Reports preliminary FY24 revenue $2.76B, consensus $2.74B. Plans to launch three new cancer tests in 2025, namely Cologuard Plus, ...